Qiagen (NASDAQ:QGEN) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued on Thursday.
Other analysts have also issued reports about the stock. Commerzbank restated a “buy” rating on shares of Qiagen in a research note on Wednesday, July 25th. Deutsche Bank restated a “buy” rating on shares of Qiagen in a research note on Friday, August 3rd. Barclays restated a “buy” rating and set a $43.00 target price on shares of Qiagen in a research note on Thursday, September 6th. Zacks Investment Research upgraded shares of Qiagen from a “sell” rating to a “hold” rating in a research note on Friday, August 3rd. Finally, Bank of America upped their target price on shares of Qiagen from $38.00 to $39.00 and gave the stock a “neutral” rating in a research note on Thursday, August 2nd. One analyst has rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the stock. Qiagen has an average rating of “Hold” and an average target price of $38.88.
Shares of QGEN opened at $34.36 on Thursday. Qiagen has a 1 year low of $30.20 and a 1 year high of $39.45. The company has a current ratio of 5.07, a quick ratio of 4.59 and a debt-to-equity ratio of 0.69.
Qiagen (NASDAQ:QGEN) last released its earnings results on Tuesday, July 31st. The company reported $0.33 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.32 by $0.01. Qiagen had a net margin of 2.85% and a return on equity of 11.74%. The firm had revenue of $377.20 million for the quarter, compared to analyst estimates of $376.89 million. As a group, research analysts forecast that Qiagen will post 1.34 earnings per share for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the stock. First Trust Advisors LP purchased a new position in Qiagen in the second quarter valued at approximately $61,777,000. OppenheimerFunds Inc. purchased a new position in Qiagen in the second quarter valued at approximately $56,507,000. BlackRock Inc. increased its stake in Qiagen by 28.4% in the second quarter. BlackRock Inc. now owns 6,174,536 shares of the company’s stock valued at $223,272,000 after purchasing an additional 1,365,517 shares during the last quarter. RTW Investments LP purchased a new position in Qiagen in the second quarter valued at approximately $19,143,000. Finally, Assenagon Asset Management S.A. increased its stake in Qiagen by 58.2% in the second quarter. Assenagon Asset Management S.A. now owns 1,089,825 shares of the company’s stock valued at $39,457,000 after purchasing an additional 400,828 shares during the last quarter. Hedge funds and other institutional investors own 62.23% of the company’s stock.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
See Also: Growth Stocks, What They Are, What They Are Not
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.